Molina Healthcare MOH
Molina Healthcare is a US health insurer offering Medicaid and Medicare plans, managing government-sponsored health programs for low-income populations. Molina Healthcare shows solid financial health (net cash, DN/EBITDA -12.72) but severe operational deterioration: revenue -5.7% and earnings -75.3%, with an operating margin of only 1.40% and negative ROE. Forward valuation (P/E 19.59) is not demanding, but the business is under pressure from rising medical costs and the exit from its Medicare Advantage drug plans.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Molina Healthcare is a US health insurer offering Medicaid and Medicare plans, managing government-sponsored health programs for low-income populations. Molina Healthcare shows solid financial health (net cash, DN/EBITDA -12.72) but severe operational deterioration: revenue -5.7% and earnings -75.3%, with an operating margin of only 1.40% and negative ROE. Forward valuation (P/E 19.59) is not demanding, but the business is under pressure from rising medical costs and the exit from its Medicare Advantage drug plans.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.6 |
| Quality / Moat | 3.8 |
| Valuation | 5.3 |
| Growth | 0.8 |
| Dividend | 1.5 |
| Momentum | 3.7 |
| Risk & Context | 7.0 |
OVERALL SCORE: 4.4/10
Context and risks
Molina's business depends on government funding (Medicaid/Medicare) and is subject to regulatory rate reviews and medical cost requirements. The rising rate environment does not materially affect its balance sheet (net cash), but regulatory pressure on managed care margins is a structural risk.
News considered in the analysis
- Molina to End Its Medicare Advantage Drug Plans on December 31. The Decision Was Announced in February. The Letter Telling Members Arrives in October — La salida de los planes de medicamentos de Medicare Advantage reduce su oferta y puede afectar la competitividad, aunque la decisión se conoce desde febrero y el impacto en beneficios es limitado.
- Can Oscar Health Sustain Its Profit Rebound as Medical Costs Rise? — Artículo sobre un competidor (Oscar Health) sin información nueva sobre Molina.
- UNH vs. MOH: Which Managed Care Stock Looks More Attractive? — Comparativa genérica entre dos valores sin información nueva material.
- How Centene's Strong Cash Flow Is Reshaping Its Balance Sheet — Noticia sobre Centene, un competidor, sin impacto directo en Molina.
- Molina Healthcare (MOH) Pulls Back Following Recent Weakness, Is The Stock Cheap? — Artículo de opinión sobre la valoración sin información nueva.
Verdict: Hold; wait for signs of stabilization in the medical cost ratio and revenue growth before considering an entry.
Main risk: The main risk is regulatory and cost pressure on Medicaid/Medicare margins, already reflected in the operating margin of only 1.40% and the -75.3% earnings decline.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →